top of page
  • LinkedIn
  • Twitter

It's time to develop personalized cell therapies for the care of chronic wounds.

​Therapy for Chronic Wounds

​Healiva® is a patient-centric Swiss Biotech company developing personalized therapies to improve patients’ quality of life. We are advancing a multi-pronged approach to address patient needs by integrating cell therapies, enzyme technology, and medical devices to create tailored solutions for chronic wounds. As the first Biotech to develop multiple end-to-end, intuitive wound care products, we ensure they remain both personalized and affordable.

Mission

Our mission is to develop a portfolio of innovative, personalized, and affordable therapies for chronic wounds, addressing key pain points in the patient care pathway. A major gap remains in the current treatment paradigm, as no permanent therapy for non-healing wounds currently exists. We are actively developing solutions to bridge this gap and transform wound care.

Test Tubes

Wounds: A sizeable problem

156M

Chronic wound patients worldwide 

​

2-3% of the elderly have painful Venous/Arterial Leg Ulcers


25% of diabetics have disabling diabetic foot ulcers

9.7M

Venous leg ulcers and 

10M

Diabetic Foot ulcers patients

€21.7B

in 2022 according to PitchBook Data

8%

CAGR by 2026

A group of people talking with tablet PC in hand

Pipeline Products

Healiva Technological Breakthroughs 

Healiva products

Indication

Pre-clinical discovery

Pre-clinical development

Ph I/IIa

Ph IIb

Ph III

Market phase

AQUAtryp

Acute & chronic wounds

Healiva 004

VLUs chronic wounds

Healiva 002

VLUs chronic wounds

Epidex

Severe VLUs / chronic wounds

Work with
us

Fill the form :
bottom of page